FDA Approval of Bixlenvo: AWPCAB Demands Focus on African Girls and Women
AWPCAB welcomes the U.S. FDA approval of Bixlenvo (bictegravir and lenacapavir) and calls for…
Read storyThe AWPCAB editorial team — advancing HIV prevention choice and accountability through the voices and leadership of African women and girls across Eastern and Southern Africa.

AWPCAB welcomes the U.S. FDA approval of Bixlenvo (bictegravir and lenacapavir) and calls for…
Read story“You’re not going to be the same person when you leave here.” It was…
Read storySOUTH AFRICA – South Africa’s launch of Lenacapavir marks an important moment in the…
Read storyOn 14 May 2026, Yvette Raphael, Executive Director of APHA and Chair of the…
Read storyStatement Adopted at the Annual AWPCAB Meeting, Lilongwe, Malawi 20–22 April 2026 The African…
Read storyLONDON – Advocates for the Prevention of HIV in Africa (APHA) Executive Director and…
Read storyThe African Women Prevention Community Accountability Board extends its heartfelt congratulations to Ms. Yvette…
Read storyApril 15, 2025 The African Women Prevention Community Accountability Board (AWPCAB) convened in Dar…
Read storyI commit to championing HIV prevention choice for women and girls in Africa by…
Read story